Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide ...

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Frank Colombo, managing director at Viridian Capital Advisors, discusses the cannabis industry’s decreasing M&A activity and what it means.

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

What this suggests, at best, is a different model of protest movement: highly decentralized, moving at a snail’s pace, more a slog than a resistance. “Something is happening,” the journalist Ali ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

The backlash and furor surrounding the new Garmin Connect+ subscription service has been so intense since its announcement ...